Production (Stage)
Dianthus Therapeutics, Inc.
DNTH
$18.31
-$0.98-5.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.07% | 190.15% | 135.06% | 92.26% | 83.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.07% | 190.15% | 135.06% | 92.26% | 83.61% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 33.07% | 190.15% | 135.06% | 92.26% | 83.61% |
| SG&A Expenses | 30.09% | 47.43% | -25.16% | 140.65% | 143.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.46% | 147.83% | 92.24% | 88.83% | 129.42% |
| Operating Income | -85.93% | -146.34% | -89.73% | -88.55% | -132.25% |
| Income Before Tax | -114.66% | -169.24% | -70.52% | -58.05% | -93.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -114.66% | -169.24% | -70.52% | -58.05% | -93.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.66% | -169.24% | -70.52% | -58.05% | -93.93% |
| EBIT | -85.93% | -146.34% | -89.73% | -88.55% | -132.25% |
| EBITDA | -86.01% | -146.52% | -89.80% | -88.58% | -132.39% |
| EPS Basic | -53.91% | -13.87% | 80.54% | 95.96% | 93.39% |
| Normalized Basic EPS | -57.86% | -13.24% | 80.30% | 95.96% | 93.14% |
| EPS Diluted | -53.91% | -13.87% | 80.54% | 95.96% | 93.39% |
| Normalized Diluted EPS | -57.86% | -13.24% | 80.30% | 95.96% | 93.14% |
| Average Basic Shares Outstanding | 39.45% | 136.43% | 776.31% | 3,812.10% | 2,834.21% |
| Average Diluted Shares Outstanding | 39.45% | 136.43% | 776.31% | 3,812.10% | 2,834.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |